European Journal of Hospital Pharmacy: Science and Practice最新文献

{"title":"Frequency of measuring body weight in (sub)populations of patients with cancer treated with chemotherapy.","authors":"Shirley Kemps, Mostafa Soleyman, Harmen Huls, Mariette Labots, Mirjam Crul","doi":"10.1136/ejhpharm-2021-003215","DOIUrl":"10.1136/ejhpharm-2021-003215","url":null,"abstract":"<p><strong>Objectives: </strong>Most cytostatics used in cancer treatment are dosed on body surface area (BSA). To administer an appropriate dose it is therefore necessary to know the patient's correct body weight. However, evidence is lacking on how often, after initiation of treatment, body weight should be measured to recalculate BSA. We aimed to assess the relevance of weight measurements during chemotherapy treatment.</p><p><strong>Methods: </strong>Over a 2 year period we analysed BSA changes in adult patients undergoing chemotherapy treatment. The frequency of and median time to ≥10% BSA change was determined. We assumed a 10% BSA change required dose adjustment and was therefore clinically relevant.</p><p><strong>Results: </strong>Using a database query, data from 2276 patients were used for descriptive statistics, life table analyses and generalised estimating equations. The frequency of ≥10% BSA change occurred in a maximum of 7.6% of the patients, depending on the tumour type. Descriptive statistics in the indications with more than 100 patients showed that BSA changes of ≥10% occurred after 84 days. The groups with the earliest BSA changes were patients with acute leukaemia, lymphoma and pancreatic cancer.</p><p><strong>Conclusions: </strong>Our observations from real-world data indicate it is safe to omit the current requirement for monthly weight measurements. We advise that during chemotherapy, measuring the body weight in patients who have acute leukaemia, lymphoma or pancreatic cancer or who are under 20 years of age, should be performed at least every 3 months. For other patients, extending this period to a 6-monthly weight measurement should be considered.</p>","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85161300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-141 Analysis of ceftaroline associated neutropenia","authors":"L. García Basas, A. Gago, J. Sáez De La Fuente, AM Álvarez Díaz","doi":"10.1136/EJHPHARM-2021-EAHPCONF.260","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.260","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85573034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-209 Anticholinergic burden and risk of adverse events in patients from a Spanish nursing home","authors":"H. Rodríguez Ramallo, E. Prado Mel, R. Ramos Romero, MI Galván-Borrás, JC Huarte Mendicoa, B. Fernandez Rubio","doi":"10.1136/EJHPHARM-2021-EAHPCONF.328","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.328","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76813329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-265 Cemiplimab for the treatment of relapse of a cutaneous squamous cell carcinoma in an adult patient: a case report","authors":"J. D. Valencia, R. T. Bermejo, L. Rodelo, I. Castillo","doi":"10.1136/EJHPHARM-2021-EAHPCONF.97","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.97","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82969315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-124 Anticoagulation management within a hospital setting: identifying risk factors affecting patient safety","authors":"K. Noerens, N Van Tittelboom, A Van Buyten, H. Vandekerckhove","doi":"10.1136/EJHPHARM-2021-EAHPCONF.243","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.243","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84115103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1ISG-025 Budget impact analysis of biosimilar adalimumab versus reference adalimumab","authors":"C. Morell, JM Gonzalez Puyuelo, Mp Monforte Gasque, N. L. Andújar, M. D. Olmo, E. Gallardo","doi":"10.1136/EJHPHARM-2021-EAHPCONF.6","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.6","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77998743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5PSQ-137 Adequacy of diagnosis and treatment of pharyngotonsillitis","authors":"C. Salom, J. Blade, C. Campabadal, F. Bejarano, C. Torrente, M. Piqueras, N. Marco, L. Castillo, M. Roch, A. Sanjuan, L. Canadell","doi":"10.1136/EJHPHARM-2021-EAHPCONF.256","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.256","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82190225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-334 Influence of anthropometric, demographic and therapeutic factors on serum concentrations of anti-TNF drugs","authors":"S. Giménez, J. Polo, A. Sendra, P. Llopis, M. Climente","doi":"10.1136/EJHPHARM-2021-EAHPCONF.166","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.166","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78703086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-372 Pharmaceutical interventions in hospitalised patients during the first wave of the SARS-CoV-2 pandemic","authors":"A. Sancho, B. García, A. Villaescusa, L. L. Lopez, J. Amigo, E. Albert, N. Martínez","doi":"10.1136/EJHPHARM-2021-EAHPCONF.204","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.204","url":null,"abstract":"Background and importanceThe activity of pharmacy services increased during the first wave of the SARS-Cov-2 pandemic An example of this was the activity carried out during the validation of inpatient treatments Aim and objectivesTo evaluate pharmaceutical interventions carried out in a second level hospital during the pandemic and compare them with those in the same period of the previous year Material and methodsThis was a retrospective study All pharmaceutical interventions between March and May 2020 (pandemic period: P) and those between March and May 2019 (pre-pandemic period: pre-P) were reviewed Data collected were: number of interventions, hospital stay, intervention rate (number of interventions × 1000 hospital stays), therapeutic group involved and type of intervention Data analysis: Stata V 15 1 The χ2 Mantel–Haenszel test was used to compare intervention rates and the χ2 Pearson to compare proportions ResultsThe number of interventions was 690 versus 115, and the number of hospital stays was 27 415 versus 27 062 for the P and pre-P periods, respectively The intervention rate (P vs pre-P) was 25 2×1000 stays versus 4 2×1000 stays (χ2 Mantel–Haenszel, p&lt;0 0001) Therapeutic groups involved (P vs pre-P, respectively) were: P01-antiparasitics/hydroxychloroquine (40% vs 0%), J-01-antibiotics and J05-antivirals (17% vs 19%), N05-antipsychotics (7% vs 6%), B01-anticoagulants antiaggregants (6% vs 15%), N-02 analgesics (5% vs 21%) and other groups (25% vs 39%) Statistically significant differences were found between both distributions (χ2 Pearson, p&lt;0,001) Type of interventions (P vs pre-P, respectively): drug interaction monitoring (40% vs 11%), stop treatment (26% vs 17%), dosage change (26% vs 60%) and other interventions (8% vs 12%) Both distributions (P and pre-P) were compared, and there were statistically significant differences between them (χ2 Pearson, p&lt;0,001) Conclusion and relevanceDuring the first wave of the SARS-CoV-2 pandemic, activity related to the validation of inpatients treatments increased significantly in our centre The acceptance rate of interventions was not collected but it should be considered for future studies The therapeutic groups involved in the pharmaceutical interventions differed between the P and pre-P periods In the P period, those related to antiparasitic drugs (which includes hydroxychloroquine) increased significantly Types of interventions were also different between both periods In the P period, the interventions related to drug interactions and excessive durations of treatments were the most frequent Both types were interventions related to the safety of treatments during the pandemic References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88999341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2SPD-037 Analysis of drug dispenses outside the hospital guide in a psychiatric hospital","authors":"J. Costa, EM Robles Blazquez, Jm Gonzalez, M. Guzman","doi":"10.1136/EJHPHARM-2021-EAHPCONF.20","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.20","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89173704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}